Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.